HOME >> BIOLOGY >> NEWS
Scientists follow familiar TRAIL to new cancer therapy

A new study identifies a combination therapy that may sensitize human cancer cells to a promising treatment currently being used in clinical trials. The research, published in the July issue of the journal Cancer Cell, published by Cell Press, provides a pharmacological method for enhancing the potency and effectiveness of a tumor necrosis factor (TNF) death receptor ligand against a variety of human cancers.

Potency and lack of toxicity to normal tissues make activation of TNF-a-related apoptosis-inducing ligand (TRAIL) death receptor signaling an attractive and exciting target for cancer therapy, and it is currently being tested in clinical trials. However, most cancer cells have defects in their ability to die via a cell death pathway called apoptosis, and unfortunately, TRAIL therapy is not effective in cells that have certain defects in apoptotic pathways. Dr. Wafik S. El-Deiry from the University of Pennsylvania School of Medicine and colleagues designed a series of studies to gain a better understanding of TRAIL-associated cell signaling pathways in cancer cells and to look for ways to pharmacologically optimize TRAIL therapy.

Dr. El-Deirys group had previously established that c-Myc is a key mediator of TRAIL-induced apoptosis and that cancer cells lacking c-Myc and a functional apoptotic pathway were resistant to TRAIL. In the current study, the researchers demonstrated that expression of c-Myc in TRAIL-resistant human colon cancer cells sensitized the cells to TRAIL, even when the cells had intrinsic apoptotic defects. The researchers observed that TRAIL induced expression of two potent antiapoptotic molecules, Mcl-1 and cIAP2, and that c-Myc repressed both molecules.

The researchers also discovered that the multikinase inhibitor sorafenib prevented TRAIL-mediated induction of Mcl-1 and cIAP2, and although it had little effect on the killing of TRAIL-resistant cells when administered alone, combination with TRAIL caused
'"/>

Contact: Erin Doonan
edoonan@cell.com
617-397-2802
Cell Press
9-Jul-2007


Page: 1 2

Related biology news :

1. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
2. Scientists prove that disputed Korean stem cell line comes from an unfertilized egg and not cloning
3. Scientists move closer to bio-engineered bladders
4. Scientists find stem cell switch
5. Scientists discover new way to study nanostructures
6. Scientists a step closer to understanding how anaesthetics work in the brain
7. Scientists to make news at Computational Biology Conference
8. Accident-prone? Scientists link brain function to knee injuries
9. Scientists take next step in understanding potential target for ovarian cancer treatment
10. Scientists find brown fat master switch
11. Scientists identify 2 distinct Parkinsons networks

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/21/2019)... ... December 20, 2019 , ... The City of Tampa ... SAGICO was on hand to honor these heroes. Tampa welcomed these most-highly decorated USA ... organizations and community leaders honored these distinguished service members. , The Medal of Honor, ...
(Date:12/18/2019)... ... December 17, 2019 , ... PM360, a ... and diagnostics industries, has named Pharmafusion LLC as one of the most innovative ... company and its founder/CEO Jonathan Retano. Earlier in the year, Pharmafusion was featured ...
(Date:12/14/2019)... , ... December 11, 2019 , ... ... solutions for the food and beverage industry won the 2019 Food Ingredient Europe’s ... to improve the rapidly growing plant-based foods category. Fiberstar who was one of ...
Breaking Biology News(10 mins):
(Date:11/27/2019)... , ... November 25, 2019 , ... ... has announced the company’s first robotic-assisted and navigated surgery in the UK. The ... (NHS) by acclaimed spine surgeons, Dr. Syed Aftab and Dr. Alexander Montgomery. The ...
(Date:11/20/2019)... ... November 20, 2019 , ... Defense and aerospace market intelligence ... generation units from 2019-2028. The value of this production is $728 million in ... worth $569 million. , Reference to 2017 is important, as that was ...
(Date:11/12/2019)... , ... November 12, 2019 ... ... enterprise software solutions for biopharmaceutical R&D, today announced that Immatics Biotechnologies ... adopted Genedata Biologics® to streamline their R&D operations related to ...
(Date:11/12/2019)... , ... November 12, 2019 , ... ... ever to educate Americans about the deadly healthcare-associated infection C. diff. The campaign, ... survivors of the epidemic, which kills at least 30,000 people in the U.S. ...
Breaking Biology Technology:
Cached News: